Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test any good and bad effects of the study drugs called
Pembrolizumab and Entinostat when used in combination to treat lymphoma. This combination
could shrink the lymphoma but it could also cause side effects. Researchers also hope to
learn whether adding entinostat to pembrolizumab can be more effective for patients with
lymphoma than either drug alone.